Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated whether anti-Saccharomyces cerevisiae antibody (ASCA) titers are associated with diagnostic findings, disease activity, Paris classification phenotypes, and persistence after infliximab (IFX) treatment in children with Crohn’s disease (CD). We also investigated the role of ASCA as a predictor of mucosal healing (MH) and clinical remission (CR). Methods: This study included 61 CD patients aged 19 years or younger who were diagnosed and treated between September 2010 and January 2019 and followed for at least 1 year. ASCA was regularly measured at the diagnosis of CD and at least 1 year after IFX therapy. Results: The average follow-up period was 3.8±3.4 years (range, 1.0 to 7.2 years). Regression analysis showed that the ASCA titer was the only factor associated with Simple Endoscopic Score for Crohn's Disease (SES-CD) or CR among all the parameters. In patients who had achieved MH (SES-CD=0), ASCA immunoglobulin G (IgG) was not associated with MH, but in patients without MH, ASCA IgG was associated with SES-CD (p=0.005) and CR (p<0.001). The cutoff value of ASCA IgG in patients with CR was 21.8 units. However, there was no difference in the relapse rate between the ASCA IgG-positive and -negative groups during the follow-up period. Conclusions: In patients who have not achieved MH, ASCA IgG is closely related to mucosal damage and CR. Unlike Western studies, ASCA IgG may be more helpful in predicting prognosis than immunoglobulin A in Korean patients, but it is not an appropriate indicator to predict the relapse of CD.
Abstract
Background/Aims: We evaluated whether anti-Saccharomyces cerevisiae antibody (ASCA) titers are associated with diagnostic findings, disease activity, Paris classification phenotypes, and persistence after infliximab (IFX) treatment in children with Crohn’s disease (CD). We also investigated the role of ASCA as a predictor of mucosal healing (MH) and clinical remission (CR). Methods: This study included 61 CD patients aged 19 years or younger who were diagnosed and treated between September 2010 and January 2019 and followed for at least 1 year. ASCA was regularly measured at the diagnosis of CD and at least 1 year after IFX therapy. Results: The average follow-up period was 3.8±3.4 years (range, 1.0 to 7.2 years). Regression analysis showed that the ASCA titer was the only factor associated with Simple Endoscopic Score for Crohn's Disease (SES-CD) or CR among all the parameters. In patients who had achieved MH (SES-CD=0), ASCA immunoglobulin G (IgG) was not associated with MH, but in patients without MH, ASCA IgG was associated with SES-CD (p=0.005) and CR (p<0.001). The cutoff value of ASCA IgG in patients with CR was 21.8 units. However, there was no difference in the relapse rate between the ASCA IgG-positive and -negative groups during the follow-up period. Conclusions: In patients who have not achieved MH, ASCA IgG is closely related to mucosal damage and CR. Unlike Western studies, ASCA IgG may be more helpful in predicting prognosis than immunoglobulin A in Korean patients, but it is not an appropriate indicator to predict the relapse of CD.
참고문헌 (29)
- 홍석진, "Characteristics and Incidence Trends for Pediatric Inflammatory Bowel Disease in Daegu-Kyungpook Province in Korea: a Multi-Center Study", Journal of Korean Medical Science, 33(18), pp.1~8 (2018), 대한의학회
- Benchimol EI, "Trends in epidemiology of pediatric inflammatory bowel disease in Canada : distributed network analysis of multiple population-based provincial health administrative databases", Am J Gastroenterol, 112, pp.1120~1134 (2017)
- El-Matary W, "Inflammatory bowel disease in children of Manitoba : 30 years’ experience of a tertiary center", J Pediatr Gastroenterol Nutr, 59, pp.763~766 (2014)
- 이강문, "Crohn’s disease in Korea: past, present, and future", The Korean Journal of Internal Medicine, 29(5), pp.558~570 (2014), 대한내과학회[DOI]
- Zhou G, "ASCA, ANCA, ALCA and many more: are they useful in the diagnosis of inflammatory bowel disease?", Dig Dis, 34, pp.90~97 (2016)
- Levine A, "Pediatric inflammatory bowel disease: is it different?", Dig Dis, 27, pp.212~214 (2009)
- Main J, "Antibody to Saccharomyces cerevisiae(bakers’ yeast)in Crohn’s disease", BMJ, 297, pp.1105~1106 (1988)
- Lewis JD, "The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease", Gastroenterology, 140, pp.1817~1826 (2011)
- El-Matary W, "Anti-Saccharomyces cerevisiae antibody titres correlate well with disease activity in children with Crohn’s disease", Acta Paediatr, 104, pp.827~830 (2015)
- Kim BC, "Clinical significance of anti-Saccharomyces cerevisiae antibody(ASCA)in Korean patients with Crohn’s disease and its relationship to the disease clinical course", Dig Liver Dis, 39, pp.610~616 (2007)
- Peeters M, "Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease", Am J Gastroenterol, 96, pp.730~734 (2001)
- Forcione DG, "Anti-Saccharomyces cerevisiae antibody(ASCA)positivity is associated with increased risk for early surgery in Crohn’s disease", Gut, 53, pp.1117~1122 (2004)
- Zhang Z, "Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn’s disease : a meta-analysis", Dig Dis Sci, 57, pp.2944~2954 (2012)
- Ruemmele FM, "Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease", Gastroenterology, 115, pp.822~829 (1998)
- Teml A, "Anti-Saccharomyces cerevisiae antibodies : a stable marker for Crohn’s disease during steroid and 5-aminosalicylic acid treatment", Am J Gastroenterol, 98, pp.2226~2231 (2003)
- Oshitani N, "Decreased antiSaccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn’s disease", J Gastroenterol Hepatol, 15, pp.1400~1403 (2000)
- Esters N, "Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease", Am J Gastroenterol, 97, pp.1458~1462 (2002)
- Dubinsky MC, "Genome wide association(GWA)predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 16, pp.1357~1366 (2010)
- Chandrakumar A, "Anti-Saccharomyces cerevisiae antibodies as a prognostic biomarker in children with Crohn disease", J Pediatr Gastroenterol Nutr, 69, pp.82~87 (2019)
- Miheller P, "Recommendations for identifying Crohn’s disease patients with poor prognosis", Expert Rev Clin Immunol, 9, pp.65~75 (2013)
- Rieder F, "Clinical utility of anti-glycan antibodies in pediatric Crohn’s disease in comparison with an adult cohort", Inflamm Bowel Dis, 18, pp.1221~1231 (2012)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Hyams J, "Evaluation of the pedi-atric Crohn disease activity index : a prospective multicenter experience", J Pediatr Gastroenterol Nutr, 41, pp.416~421 (2005)
- Canani RB, "Effects of disease activity on anti-Saccharomyces cerevisiae antibodies : implications for diagnosis and follow-up of children with Crohn’s disease", Inflamm Bowel Dis, 10, pp.234~239 (2004)
- Vasiliauskas EA, "Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics", Gut, 47, pp.487~496 (2000)
- Halfvarson J, "AntiSaccharomyces cerevisiae antibodies in twins with inflammatory bowel disease", Gut, 54, pp.1237~1243 (2005)
- Quinton JF, "Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease : prevalence and diagnostic role", Gut, 42, pp.788~791 (1998)
- Rieder F, "Characterization of changes in serum anti-glycan antibodies in Crohn’s disease : a longitudinal analysis", PLoS One, 6, pp.e18172~ (2011)
- Targan SR, "Antibodies to CBir1flagellin define a unique response that is associated independently with complicated Crohn’s disease", Gastroenterology, 128, pp.2020~2028 (2005)